{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:56:38Z","timestamp":1790502998394,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/s41388-017-0044-8","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T09:06:48Z","timestamp":1515143208000},"page":"1369-1385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome"],"prefix":"10.1038","volume":"37","author":[{"given":"Simona","family":"di Martino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Azzurra","family":"Amoreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nuvoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Strano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Facciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Alessandrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-8605","authenticated-orcid":false,"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"De Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cioce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"44_CR1","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/1078-0432.CCR-14-1213","volume":"21","author":"A Pribluda","year":"2015","unstructured":"Pribluda A, de la Cruz CC, Jackson EL. Intratumoral heterogeneity: from diversity comes resistance. Clin Cancer Res 2015;21:2916\u201323.","journal-title":"Clin Cancer Res"},{"key":"44_CR2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201101131","volume":"4","author":"NA Saunders","year":"2012","unstructured":"Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 2012;4:675\u201384.","journal-title":"EMBO Mol Med"},{"key":"44_CR3","volume":"7","author":"D Basu","year":"2012","unstructured":"Basu D, Reyes-Mugica M, Rebbaa A. Role of the beta catenin destruction complex in mediating chemotherapy-induced senescence-associated secretory phenotype. PLoS One 2012;7:e52188.","journal-title":"PLoS One"},{"key":"44_CR4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368\u201372.","journal-title":"Nature"},{"key":"44_CR5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jtcvs.2009.11.072","volume":"140","author":"AA Mujoomdar","year":"2010","unstructured":"Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg 2010;140:352\u20135.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"44_CR6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"44_CR7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"M Carbone","year":"2012","unstructured":"Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44\u201358.","journal-title":"J Cell Physiol"},{"key":"44_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","volume":"1203","author":"JM Hillegass","year":"2010","unstructured":"Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010;1203:7\u201314.","journal-title":"Ann N Y Acad Sci"},{"key":"44_CR9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ncb2784","volume":"15","author":"JC Acosta","year":"2013","unstructured":"Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013;15:978\u201390.","journal-title":"Nat Cell Biol"},{"key":"44_CR10","first-page":"354","volume":"21","author":"J Campisi","year":"2011","unstructured":"Campisi J, Andersen JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol 2011;21:354\u20139.","journal-title":"Semin Cancer Biol"},{"key":"44_CR11","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Coppe","year":"2008","unstructured":"Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853\u201368.","journal-title":"PLoS Biol"},{"key":"44_CR12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.molmed.2008.07.001","volume":"14","author":"I Bussing","year":"2008","unstructured":"Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 2008;14:400\u20139.","journal-title":"Trends Mol Med"},{"key":"44_CR13","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1038\/onc.2011.485","volume":"31","author":"C Canino","year":"2012","unstructured":"Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2012;31:3148\u201363.","journal-title":"Oncogene"},{"key":"44_CR14","doi-asserted-by":"crossref","first-page":"12637","DOI":"10.18632\/oncotarget.3703","volume":"6","author":"C Canino","year":"2015","unstructured":"Canino C, Luo Y, Marcato P, Blandino G, Pass HI, Cioce M, A STAT3-NFkB\/DDIT3\/CEBPbeta axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget. 2015;6:12637\u201353.","journal-title":"Oncotarget"},{"key":"44_CR15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4161\/cc.10.9.15486","volume":"10","author":"P Marcato","year":"2011","unstructured":"Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378\u201384.","journal-title":"Cell Cycle"},{"key":"44_CR16","first-page":"237ra268","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 2014;6:237ra268.","journal-title":"Sci Transl Med"},{"key":"44_CR17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cell.2012.06.047","volume":"150","author":"M Taipale","year":"2012","unstructured":"Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, et al. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell. 2012;150:987\u20131001.","journal-title":"Cell"},{"key":"44_CR18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537\u201349.","journal-title":"Nat Rev Cancer"},{"key":"44_CR19","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/onc.2015.213","volume":"35","author":"S Busacca","year":"2016","unstructured":"Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, et al. Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene. 2016;35:1483\u201392.","journal-title":"Oncogene"},{"key":"44_CR20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature21064","volume":"542","author":"G Genovese","year":"2017","unstructured":"Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017;542:362\u20136.","journal-title":"Nature"},{"key":"44_CR21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10637-014-0095-4","volume":"32","author":"S He","year":"2014","unstructured":"He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs 2014;32:577\u201386.","journal-title":"Invest New Drugs"},{"key":"44_CR22","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1038\/onc.2013.439","volume":"33","author":"CH Lai","year":"2014","unstructured":"Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, et al. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2014;33:4867\u201376.","journal-title":"Oncogene"},{"key":"44_CR23","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","volume":"18","author":"T Shimamura","year":"2012","unstructured":"Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012;18:4973\u201385.","journal-title":"Clin Cancer Res"},{"key":"44_CR24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10637-015-0307-6","volume":"34","author":"MK Thakur","year":"2016","unstructured":"Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, et al. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs 2016;34:112\u20138.","journal-title":"Invest New Drugs"},{"key":"44_CR25","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","volume":"19","author":"MA Socinski","year":"2013","unstructured":"Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068\u201377.","journal-title":"Clin Cancer Res"},{"key":"44_CR26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","volume":"11","author":"W Ying","year":"2012","unstructured":"Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012;11:475\u201384.","journal-title":"Mol Cancer Ther"},{"key":"44_CR27","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-12-0998","volume":"12","author":"EB Garon","year":"2013","unstructured":"Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, et al. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 2013;12:890\u2013900.","journal-title":"Mol Cancer Ther"},{"key":"44_CR28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-08-0758","volume":"8","author":"K Lundgren","year":"2009","unstructured":"Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921\u20139.","journal-title":"Mol Cancer Ther"},{"key":"44_CR29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","volume":"14","author":"S Ohkubo","year":"2015","unstructured":"Ohkubo S, Kodama Y, Muraoka H, Hitotsumachi H, Yoshimura C, Kitade M, et al. TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther 2015;14:14\u201322.","journal-title":"Mol Cancer Ther"},{"key":"44_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-62703-239-1_12","volume":"965","author":"KM Aird","year":"2013","unstructured":"Aird KM, Zhang R. Detection of senescence-associated heterochromatin foci (SAHF). Methods Mol Biol 2013;965:185\u201396.","journal-title":"Methods Mol Biol"},{"key":"44_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00412-014-0469-6","volume":"123","author":"A Corpet","year":"2014","unstructured":"Corpet A, Stucki M, Chromatin maintenance and dynamics in senescence: a spotlight on SAHF formation and the epigenome of senescent cells. Chromosoma. 2014;123:423\u201336.","journal-title":"Chromosoma"},{"key":"44_CR32","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/nprot.2009.191","volume":"4","author":"F Debacq-Chainiaux","year":"2009","unstructured":"Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009;4:1798\u2013806.","journal-title":"Nat Protoc"},{"key":"44_CR33","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.183","volume":"3","author":"J Cahu","year":"2012","unstructured":"Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012;3:e446.","journal-title":"Cell Death Dis"},{"key":"44_CR34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10522-015-9610-z","volume":"17","author":"D Alimbetov","year":"2016","unstructured":"Alimbetov D, Davis T, Brook AJ, Cox LS, Faragher RG, Nurgozhin T, et al. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology. 2016;17:305\u201315.","journal-title":"Biogerontology"},{"key":"44_CR35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI39397","volume":"120","author":"C Ginestier","year":"2010","unstructured":"Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485\u201397.","journal-title":"J Clin Invest"},{"key":"44_CR36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs 2015;33:1100\u20137.","journal-title":"Invest New Drugs"},{"key":"44_CR37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","volume":"77","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, et al. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2016;77:997\u20131003.","journal-title":"Cancer Chemother Pharmacol"},{"key":"44_CR38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015;21:77\u201386.","journal-title":"Clin Cancer Res"},{"key":"44_CR39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-4939-3191-0_13","volume":"1379","author":"C Canino","year":"2016","unstructured":"Canino C, Cioce M. Isolation of chemoresistant cell subpopulations. Methods Mol Biol 2016;1379:139\u201350.","journal-title":"Methods Mol Biol"},{"key":"44_CR40","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","volume":"23","author":"T Chernova","year":"2016","unstructured":"Chernova T, Sun XM, Powley IR, Galavotti S, Grosso S, Murphy FA, et al. Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease. Cell Death Differ 2016;23:1152\u201364.","journal-title":"Cell Death Differ"},{"key":"44_CR41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","volume":"33","author":"KU Kim","year":"2005","unstructured":"Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005;33:541\u20138.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"44_CR42","first-page":"437","volume":"37","author":"L Cortes-Dericks","year":"2010","unstructured":"Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol 2010;37:437\u201344.","journal-title":"Int J Oncol"},{"key":"44_CR43","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-304","volume":"14","author":"L Cortes-Dericks","year":"2014","unstructured":"Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC Cancer 2014;14:304.","journal-title":"BMC Cancer"},{"key":"44_CR44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-3-319-06068-2_20","volume":"806","author":"S Patel","year":"2014","unstructured":"Patel S, Ngounou Wetie AG, Darie CC, Clarkson BD. Cancer secretomes and their place in supplementing other hallmarks of cancer. Adv Exp Med Biol 2014;806:409\u201342.","journal-title":"Adv Exp Med Biol"},{"key":"44_CR45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10555-010-9220-9","volume":"29","author":"AR Davalos","year":"2010","unstructured":"Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastas- Rev 2010;29:273\u201383.","journal-title":"Cancer Metastas- Rev"},{"key":"44_CR46","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1021\/pr8010974","volume":"8","author":"RA Mathias","year":"2009","unstructured":"Mathias RA, Wang B, Ji H, Kapp EA, Moritz RL, Zhu HJ, et al. Secretome-based proteomic profiling of Ras-transformed MDCK cells reveals extracellular modulators of epithelial-mesenchymal transition. J Prote Res 2009;8:2827\u201337.","journal-title":"J Prote Res"},{"key":"44_CR47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1101\/gad.625811","volume":"25","author":"M Ohanna","year":"2011","unstructured":"Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 2011;25:1245\u201361.","journal-title":"Genes Dev"},{"key":"44_CR48","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.18632\/oncotarget.1143","volume":"4","author":"M Ohanna","year":"2013","unstructured":"Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, et al. Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget. 2013;4:2212\u201324.","journal-title":"Oncotarget"},{"key":"44_CR49","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1158\/0008-5472.CAN-07-1162","volume":"67","author":"S Araki","year":"2007","unstructured":"Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67:6854\u201362.","journal-title":"Cancer Res"},{"key":"44_CR50","first-page":"367","volume":"59","author":"G Galffy","year":"1999","unstructured":"Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59:367\u201371.","journal-title":"Cancer Res"},{"key":"44_CR51","first-page":"187","volume":"11","author":"G Galffy","year":"1999","unstructured":"Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res 1999;11:187\u201394.","journal-title":"Oncol Res"},{"key":"44_CR52","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/ijc.25562","volume":"128","author":"Y Ning","year":"2011","unstructured":"Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 2011;128:2038\u201349.","journal-title":"Int J Cancer"},{"key":"44_CR53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejca.2013.09.021","volume":"50","author":"SY Park","year":"2014","unstructured":"Park SY, Han J, Kim JB, Yang MG, Kim YJ, Lim HJ, et al. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Eur J Cancer 2014;50:341\u201350.","journal-title":"Eur J Cancer"},{"key":"44_CR54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr3436","volume":"15","author":"JK Singh","year":"2013","unstructured":"Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013;15:210.","journal-title":"Breast Cancer Res"},{"key":"44_CR55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cyto.2011.06.005","volume":"56","author":"Y Wang","year":"2011","unstructured":"Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ, Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011;56:365\u201375.","journal-title":"Cytokine"},{"key":"44_CR56","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1158\/1078-0432.CCR-04-0812","volume":"10","author":"IH Benoy","year":"2004","unstructured":"Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157\u201362.","journal-title":"Clin Cancer Res"},{"key":"44_CR57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/emboj.2011.69","volume":"30","author":"A Freund","year":"2011","unstructured":"Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 2011;30:1536\u201348.","journal-title":"EMBO J"},{"key":"44_CR58","doi-asserted-by":"crossref","first-page":"aaa5612","DOI":"10.1126\/science.aaa5612","volume":"349","author":"C Kang","year":"2015","unstructured":"Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science, 2015;349:aaa5612.","journal-title":"Science,"},{"key":"44_CR59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3390\/cancers7020814","volume":"7","author":"R Gomez-Casal","year":"2015","unstructured":"Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, Wang X, et al. The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells. Cancers. 2015;7:876\u2013907.","journal-title":"Cancers"},{"key":"44_CR60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1535-7163.MCT-16-0677","volume":"16","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Huang EH, Christie I, Kurland BF, Burns TF. Acquired resistance to the Hsp90 inhibitor, ganetespib, in KRAS-Mutant NSCLC is mediated via reactivation of the ERK-p90RSK-mTOR signaling network. Mol Cancer Ther 2017;16:793\u2013804.","journal-title":"Mol Cancer Ther"},{"key":"44_CR61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CAD.0000000000000347","volume":"27","author":"X Liu","year":"2016","unstructured":"Liu X, Ban LL, Luo G, Li ZY, Li YF, Zhou YC, et al. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells. Anticancer Drugs 2016;27:417\u201326.","journal-title":"Anticancer Drugs"},{"key":"44_CR62","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/ph4111400","volume":"4","author":"PW Piper","year":"2011","unstructured":"Piper PW, Millson SH, Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals. 2011;4:1400\u201322.","journal-title":"Pharmaceuticals"},{"key":"44_CR63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, O\u2019Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165\u201376.","journal-title":"Cancer Discov"},{"key":"44_CR64","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ncb3195","volume":"17","author":"RM Laberge","year":"2015","unstructured":"Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049\u201361.","journal-title":"Nat Cell Biol"},{"key":"44_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.136","volume":"5","author":"M Cioce","year":"2014","unstructured":"Cioce M, Canino C, Goparaju C, Yang H, Carbone M, Pass HI. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis 2014;5:e1167.","journal-title":"Cell Death Dis"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0044-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-017-0044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:51Z","timestamp":1684616991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-017-0044-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["44"],"URL":"https:\/\/doi.org\/10.1038\/s41388-017-0044-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,9]]}}}